1Carmicheal J, Mitchell JB, DeGraff WG, et al. Chemosensifivity testing of human lung cancer cell lines using the MTT assay. Br J Cancer, 1988, 57(6) :540 - 547
2Ohe Y, Nakagawa K, Fujiwara Y, et al. In vitro evaluation of the new anfitumor agents KT6149, MX-Z, SM5887, menogaril,and liblomycin using cisplatin-or-adriamycin-resistant human cancer cell lines. Cancer Res, 1989, 49(10) :4098 - 4102
3Hofs HP, Wagener DJ, Bakker V. Concentration and sequence dependent synergism of ethyldeshydroxy-sparsomycin in combination with anfitumor agents. Anticancer Drugs, 1994, 5(1):35 -42
4Nozue M, Hishida M, Todoroki T, et al. Selection of three of 24 anticancer agents in poody differentiated gastric cancer cell lines evaluated by the AVC delta IC50 ratio. Anticancer Drugs, 1995,6(2) :291 - 302
5Andrew G. Bosanquet,Martin C. Bird. Degradation of melphalan in vitro: rationale for the use of continuous exposure in chemosensitivity assays[J] 1988,Cancer Chemotherapy and Pharmacology(3):211～215
8[7]Nakabayashi M,Oh WK. Neoadjuvant and adjuvant chemoth-erapy for high-risk localized prostate cancer[J]. Curr Treat Options Oncol,2004,5(5):349
9[8]Schmoll HJ,Souchon R,Krege S,et al.European consensus on diagnosis and treatment of germ cell cancer:a report of the European germ cell cancer consensus group(EGCCCG)[J]. Ann Oncol,2004,15(9):1377
10[9]Urata H,Hori H,Uchida k,et al.Strategy for the treatment of unresectable hepatoblastoma:neoadjuvant chemotherapy followed by delayed primary operation or liver transplantation[J]. Int Surg,2004,89(2):95
